HL-PIF
AssetAlso HL-PIF cap.160/2mg
Peroxisome proliferator-activated receptor alpha agonist that regulates lipid metabolism.
- Stage
- Phase 3
- Modality
- Small molecule
- Target
- Lipid and ceramide metabolism
- 1
- Indication
- 94
- Trials
- 1
- Developer
Indications
1Complex dyslipidemia
Phase 3, Completed, NCT03618797, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains3
- Owner and partners1
- Trials94
- Evidence for its targets3
- Competitors9
- Aging relevance1
- Signals2
Every asset’s record: target, stage, trials and the evidence behind it.